I think we all know Ganetespib will be approved. The clinical activity is undeniable. Just look at some of the imaging studies in the corporate presentation. The ups and downs make for great short term trading opportunities around a core position. Insiders and institutions are making nice $ on these fluctuations, all the while adding to core positions as they know the end result. Why wouldn't you?